Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
(2012).
(2011).
Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment..
Osteoporos Int. 24(7), 2127-32.
(2013). Circulating periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment..
Horm Metab Res. 46(2), 145-9.
(2014). Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment..
Expert Opin Ther Targets. 19(3), 299-306.
(2015). Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia..
Cell Rep. 11(9), 1446-57.
(2015).
(2009).
(2013). Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers..
Metabolism. 64(10), 1291-7.
(2015). Denosumab versus zoledronic acid in patients previously treated with zoledronic acid..
Osteoporos Int. 26(10), 2521-7.
(2015).
(2010). The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin, and RANKL in patients with Paget's disease of bone..
Horm Metab Res. 41(11), 846-50.
(2009).
(2012).
(2010). The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis..
Int J Cancer. 125(7), 1705-9.
(2009). Increased CD14+ and decreased CD14- populations of monocytes 48 h after zolendronic acid infusion in breast cancer patients..
Osteoporos Int. 28(3), 991-999.
(2017). Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib..
Clin Cancer Res. 15(23), 7153-60.
(2009). Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid..
J Clin Endocrinol Metab. 101(9), L89-90.
(2016). Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw..
J Clin Oncol. 27(32), 5356-62.
(2009). No effect of rosuvastatin in the zoledronate-induced acute-phase response..
Calcif Tissue Int. 88(5), 402-8.
(2011). Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid..
Endokrynol Pol. 63(4), 312-5.
(2012).
(2014).
Paget disease of the spine manifested by thoracic and lumbar epidural lipomatosis: magnetic resonance imaging findings..
Spine (Phila Pa 1976). 32(25), E789-92.
(2007). Persistent effect of zoledronic acid in Paget's disease..
Clin Exp Rheumatol. 25(3), 464-6.
(2007). Possible zoledronic acid-induced dermatomyositis..
Clin Exp Dermatol. 37(3), 309-11.
(2012).